Tag Archives: CAR T-cells

CARMA – Chimeric Antigen Receptor Macrophages

CARMA Therapeutics, a company that develops chimeric antigen receptor technology, not for T-cells (CAR-T cells), rather, for macrophages, hence the name “CARMA,” closed on an initial round of funding to advance its technologies. Continue reading

Engineering safety into CAR T-cells to address toxicities

Adoptive immunotherapy with engineered T-cells, for example, CAR T-cells (Chimeric Antigen Receptor) is associated with significant toxicities including cytokine release syndrome, neurologic toxicity, “on target/off tumor” recognition, and anaphylaxis. CAR T-cells lack the ability to respond to signals that maintain immune homeostasis. For this reason, they are effective relentless killers of cells that express the target to which they have been programmed, however, at a safety cost. Continue reading

Early Cancer Detection Company, Grail, Led by Former Google VP – Ashley P. Angelo, Contributor

Healthcare firm Grail, which has been formed by the gene sequencing company Illumina, named Jeff Huber, former Google X Senior Vice President, as its CEO in February. With Huber’s experience in developing large-scale data, Grail hopes to improve gene sequencing technology used in blood tests for early detection of cancer in asymptomatic patients so that immunotherapeutic strategies, as opposed to toxic chemotherapy, can be employed with the goal of curing cancer. Continue reading

Gene-edited donor T-cells save baby with incurable leukemia

An experimental therapy made of genetically-modified donor T-cells cured a baby with incurable leukemia: Continue reading